NeuroThera Advances Tourette Syndrome Treatment with Phase IIb Trial at Yale
Event summary
- NeuroThera Labs, a SciSparc subsidiary, has launched its Phase IIb clinical trial for SCI-110 at Yale Child Study Center.
- The trial aims to evaluate the efficacy and safety of SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults.
- SCI-110 combines dronabinol with palmitoylethanolamide to reduce tics and comorbid symptoms.
- Previous Phase IIa results showed an average tic reduction of 21% using the Yale Global Tic Severity Scale.
The big picture
NeuroThera's Phase IIb trial for SCI-110 represents a critical step in addressing the unmet medical need for effective Tourette Syndrome treatments, particularly in adults. The inclusion of prestigious clinical sites like Yale Child Study Center underscores the potential of this cannabinoid-based approach. SciSparc’s strategic focus on central nervous system disorders positions it to capitalize on advancements in neurological treatment.
What we're watching
- Clinical Progress
- The pace at which SCI-110 demonstrates efficacy and safety in the Phase IIb trial will determine its path to regulatory approval.
- Market Potential
- How NeuroThera leverages positive trial results to position SCI-110 as a leading treatment for Tourette Syndrome in adults.
- Strategic Expansion
- Whether SciSparc can capitalize on NeuroThera’s advancements to strengthen its portfolio of cannabinoid-based therapies.